Anti-Mullerian hormone levels and breast cancer risk in the study of women's health across the nation.

ABSTRACT:

Purpose

The relation of premenopausal anti-Müllerian hormone (AMH) levels with breast cancer risk has been evaluated in a few studies, but primarily in non-Hispanic White women.

Methods

We evaluated the association of AMH levels with breast cancer risk in Study of Women's Health Across the Nation (SWAN), a multi-ethnic cohort of women. At enrollment, participants had an intact uterus and ≥ 1 ovary, and ≥ 1 menstrual period in the last 3 months. AMH at first measurement was assessed in 1,529 pre- or perimenopausal women using a high-sensitivity ELISA assay; values were natural log transformed. Breast cancer diagnoses were assessed at enrollment and subsequent follow-up visits through 2018 (median 6.1 years).

Results

In total, 84 women reported an incident breast cancer

SUBMITTER: Grimes NP 

PROVIDER: S-EPMC10683710 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature